Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...

New research led by Joshua Rosenthal, PhD, of the Marine Biological Laboratory (MBL) and Eli Eisenberg, PhD, at Tel Aviv University, has revealed that octopuses and their close relatives adjust to ...

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

Over the past few years, the excitement over genome editing has moved well beyond the original CRISPR-Cas system described a decade ago, into areas such as the discovery of new Cas systems, CRISPR ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...

Maddy has a degree in biochemistry from the University of York and specializes in reporting on health, medicine, and genetics. Maddy has a degree in biochemistry from the University of York and ...

The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...

In a recent study in Nature Communications, researchers examined the adenosine-to-inosine (A-to-I) nucleoside editing of postmortem and live prefrontal cortical tissues. Researchers found that RNA ...

Using a novel method, Weizmann Institute of Science researchers map 16 types of simultaneous changes in dozens of samples; ...